Form 8-K - Current report:
SEC Accession No. 0001193125-24-030144
Filing Date
2024-02-09
Accepted
2024-02-09 16:39:05
Documents
17
Period of Report
2024-02-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d772199d8k.htm   iXBRL 8-K 28495
2 EX-5.1 d772199dex51.htm EX-5.1 11690
6 GRAPHIC g772199dsp5.jpg GRAPHIC 16783
7 GRAPHIC g772199g0207212605574.jpg GRAPHIC 2222
  Complete submission text file 0001193125-24-030144.txt   197744

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA howl-20240209.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20240209_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20240209_pre.xml EX-101.PRE 11713
18 EXTRACTED XBRL INSTANCE DOCUMENT d772199d8k_htm.xml XML 3769
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 24615647
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)